Phase I trial with a combination of docetaxel and 153Sm-lexidronam in patients with castration-resistant metastatic prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 6, 2011, Pages 670-675

  Lin, Jianqing ^a,c   Sinibaldi, Victoria J ^a   Carducci, Michael A ^a   Denmeade, Samuel ^a   Song, Danny ^a,b   DeWeese, Theodore ^a,b   Eisenberger, Mario A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

153Sm lexidronam; Docetaxel; Metastatic prostate cancer; Phase I

Indexed keywords

CODEINE; DOCETAXEL; FENTANYL; HYDROMORPHONE; LEXIDRONAM SAMARIUM SM 153; MORPHINE; OXYCODONE;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BONE DISEASE; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE SCINTISCANNING; CANCER PAIN; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TASTE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADENOCARCINOMA; ANALGESICS, NON-NARCOTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; TAXOIDS;

EID: 81055133557     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.10.003     Document Type: Article

References (24)

1. Costa L., Badia X., Chow E., et al. Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Support Care Cancer 2008, 16:879-889.
2. Bradley D.A., Hussain M., Dipaola R.S., et al. Bone directed therapies for prostate cancer. J Urol 2007, 178:S42-S48.
3. Tu S.M., Lin S.H. Current trials using bone-targeting agents in prostate cancer. Cancer J 2008, 14:35-39.
4. Storey J.A., Torti F.M. Bone metastases in prostate cancer: A targeted approach. Curr Opin Oncol 2007, 19:254-258.
5. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
6. 153Sm lexidronam. Drugs Aging 1997, 11:413-418. Discussion 419.
7. 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun 2007, 28:623-630.
8. 153Sm-ethylene diamine tetramethylene phosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 1997, 33:1583-1591.
9. Serafini A.N., Houston S.J., Resche I., et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo-controlled clinical trial. J Clin Oncol 1998, 16:1574-1581.
10. Sartor O., Reid R.H., Bushnell D.L., et al. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer 2007, 109:637-643.
11. Serafini A.N. Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases. Cancer 2000, 88:2934-2939.
12. Farhanghi M., Holmes R.A., Volkert W.A., et al. Samarium-153-EDTMP: Pharmacokinetic, toxicity, and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med 1992, 33:1451-1458.
13. Tu S.M., Millikan R.E., Mengistu B., et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomized phase II trial. Lancet 2001, 357:336-341.
14. 153Sm-lexidronam and docetaxel for the treatment of patients with hormone-refractory prostate cancer: First experience. Cancer Biother Radiopharm 2008, 23:609-618.
15. Karasawa K., Katsui K., Seki K., et al. Radiotherapy with concurrent docetaxel for advanced and recurrent breast cancer. Breast Cancer 2003, 10:268-274.
16. Mason K.A., Hunter N.R., Milas M., et al. Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 1997, 3:2431-2438.
17. Geng C.X., Zeng Z.C., Wang J.Y., et al. Docetaxel shows radiosensitization in human hepatocellular carcinoma cells. World J Gastroenterol 2005, 11:2990-2993.
18. Pradier O., Rave-Frank M., Lehmann J., et al. Effects of docetaxel in combination with radiation on human head and neck cancer cells (ZMK-1) and cervical squamous cell carcinoma cells (CaSki). Int J Cancer 2001, 91:840-845.
19. Distelmans W., Storme G. The effect of pretreatment with docetaxel (Taxotere; RP 56976) on irradiated subcutaneous MA 16/C murine tumors. J Exp Clin Cancer Res 1999, 18:167-172.
20. Kim J.S., Amorino G.P., Pyo H., et al. The novel taxane analogs, BMS-184476 and BMS-188797, potentiate the effects of radiation therapy in vitro and in vivo against human lung cancer cells. Int J Radiat Oncol Biol Phys 2001, 51:525-534.
21. 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging 2007, 34:1023-1030.
22. S. Tu DJ, Mathew P, Logothetis CJ. Phase I study of concurrent weekly docetaxel (Tax) and repeated 153Sm-Lexidronam (Sam) in androgen-independent prostate cancer (AIPC). Proceedings of the 2008 ASCO Annual meeting, Chicago, May 2008.
23. Tu S.M., Mathew P., Wong F.C., et al. Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncol 2009, 27:3319-3324.
24. Morris M.J., Pandit-Taskar N., Carrasquillo J., et al. Phase I Study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol 2009, 27:2436-2442.